UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June 9, 2004
Date of Report (date of earliest event reported)
CUTERA, INC.
(Exact name of Registrant as specified in its charter)
| State of Delaware | 000-50644 | 77-0492262 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)
(415) 657-5500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
On June 3, 2004 we increased the size of our board of directors from seven to eight members. In addition, Mark Lortz was elected to our board of directors as a Class II director. As with the other Class II directors, Mr. Lortz will stand for re-election at the 2006 annual meeting of stockholders. Mr. Lortz will replace director Guy Nohra on the Audit Committee. In connection with Mr. Lortz’s service as a director, we anticipate that he will receive an initial option grant for 30,000 shares of our Common Stock, consistent with the terms of our 2004 Equity Incentive Plan. Mr. Lortz will also receive $5,000 for each board meeting that he attends and $1,500 for each committee meeting that he attends.
On June 9, 2004, we issued a press release announcing the appointment of Mark Lortz. The press release is attached hereto as Exhibit 99.1. This Exhibit is not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), but is instead furnished. The Exhibit is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated as of June 9, 2004. |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CUTERA, INC. | ||
| By: |
/s/ Kevin P. Connors | |
| Kevin P. Connors | ||
| President and Chief Executive Officer | ||
Date: June 9, 2004
-3-
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACTS:
Cutera, Inc.
Ron Santilli
Chief Financial Officer
415-657-5500
Investor Relations
John Mills or Tom Ryan
Integrated Corporate Relations, Inc.
310-395-2215
jmills@icrinc.com
CUTERA, INC. ANNOUNCES NEW BOARD MEMBER
Brisbane, California, June 9, 2004 – Cutera, Inc. (NASDAQ:CUTR), a leading manufacturer of laser and other light-based aesthetic systems for practitioners worldwide, announced today the appointment of Mark Lortz to its Board of Directors. Mr. Lortz, an independent director, will be the newest member of Cutera’s board and will sit on its audit committee.
Commenting on the announcement, Cutera President and Chief Executive Officer Kevin Connors said, “We are pleased to have Mark join our board with his strong entrepreneurial background. Mark has played a critical role in the successful development and launch of major new products at TheraSense and LifeScan and we are looking forward to his contributions during our board sessions.”
Mr. Lortz currently serves as the Chairman, President and Chief Executive Officer of Therasense, which was recently acquired by Abbott Laboratories. Prior to TheraSense, Mr. Lortz held several positions at LifeScan, including Vice President, Operations and Group Vice President, Worldwide Business Operations. Prior to LifeScan, Mark has 18 years of experience with the General Electric Company in several divisions. He serves on the Board of IntraLase, a manufacturer of lasers for ophthalmology applications, and holds an MBA in Management from Xavier University and a BS in Engineering Science from Iowa State University.
# # #
About Cutera, Inc.
CuteraTM designs, develops, manufactures and markets the CoolGlide® family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CVTM provides permanent hair reduction on all skin types. The second generation CoolGlide Excel® incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide VantageTM added non-ablative skin therapy to the range of applications offered by the system. The CoolGlide XeoTM added the capability to treat pigmented lesions. The new Xeo SATM offers a platform for next-generation, intelligent pulsed light treatment, with an upgrade path to the CoolGlide Xeo.